Novartis AG has said that a late-stage study has shown the oral, once-daily BAF312 drug, or Siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.
The Phase III EXPAND study, the largest randomised, controlled study in secondary progressive multiple sclerosis (SPMS) to date, met its primary endpoint, compared with placebo, the Swiss drugmaker said.
"SPMS is a particularly disabling form of MS, and there is a need for effective treatment options to help delay disability progression in those living with the condition," said Vasant Narasimhan, global head of drug development and chief medical Officer for Novartis.
Source: Reuters © 2016 Reuters. (25/08/16)